Following up on last year’s approval of Vyloy (zolbetuximab) and looking to build its pipeline of antibody-drug conjugate (ADC) therapies for cancer, Astellas unveiled a licensing agreement with China’s Evopoint Biosciences on 29 May. In exchange for $130m up front and earnouts that could push the deal value well above $1bn, Astellas will obtain ex-China rights to Phase I/II CLDN.18.2-targeted XNW27011.
Key Takeaways
- Astellas will pay Evopoint $130m up front and up to $1.34bn in total for ex-China rights to a Phase I/II CLDN.18.2-targeted ADC.
Vyloy is the first US Food and Drug Administration-approved drug that targets CLDN.18.2. It was approved...
